3Spivak JL,Gascón P,Ludwig H.Anemia management in oncology and hematology.Oncologist,2009,14 Suppl 1:43-56. 被引量：1
4Luciani A,Jacobsen PB,Extermann M,et al.Fatigue and functional dependence in older cancer patients.Am J Clin Oncol,2008,31:424-430. 被引量：1
5Dubsky P,Sevelda P,Jakesz R,et al.Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.Clin Cancer Res,2008,14:2082-2087. 被引量：1
6Ho CH,Chau WK,Hsu HC,et al.Predictive risk factors and prevalence of malignancy in patients with iron deficiency anemia in Taiwan.Am J Hematol,2005,78:108-112. 被引量：1
8Annibale B,Capurso G,Chistolini A,et al.Gastrointestinal causes of refractory iron deficiency anemia in patients without gastrointestinal symptoms.Am J Med,2001,111:439-445. 被引量：1
9Ho CH,Yu YB,Wu PH.The prevalence of iron deficiency anemia and its clinical implications in patients with colorectal carcinoma.J Chin Med Assoc,2008,71:119-122. 被引量：1
10Duzgun S,Yildirmak Y,Cetinkaya F.Neutrophil hyper segmentation and thrombocytosis in children with iron deficiency anemia.Turk J Pediatr,2005,47:251-254. 被引量：1
3Singh A, Antognini JF.Perioperative pharmacology in elderly patients [J].Curr Opin Anaesthesiol, 2010,23(4) : 449-454. 被引量：1
4Brown EN ,Purdon PL.The aging brain and anesthesia [J].Curr Opin Anaesthesiol, 2013,26(4) : 414-419. 被引量：1
5Niesters M, Dahan A.Pharmacokinetic and pharmacodynamic consid- erations for NMDA receptor antagonists in the treatment of chronic neuropathic pain [J].Expert Opin Drug Metab Toxicol, 2012,8 (11) : 1409-1417. 被引量：1
6Feenstra P, Brunsteiner M, Khinast J.Prediction of drugpackaging interactions via molecular dynamics(MD) simulations[J].Int J Pharm, 2012,431 (1-2) : 26-32. 被引量：1
